Study of ST266 Versus Saline in Treating Skin Irritation From Radiation

Radiation-induced Dermatitis Clinical Trial

Official title:

Phase I Randomized, Blinded Safety and Efficacy Trial of Amnion-derived Cellular Cytokine Solution (ACCS) Versus Saline Sprayed on the Breast of Women Undergoing Radiation Therapy for Breast Cancer After Surgical Removal of the Tumor

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01714973
• Other study ID #: ST-02-12
• Status: Completed
• Phase: Phase 1
• Start date: October 2012
• Est. completion date: October 2015

Study information

• Verified date: May 2019
• Source: Noveome Biotherapeutics, formerly Stemnion
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to evaluate the safety and efficacy of ST266 in treating radiation burns of the skin in patients undergoing treatments for breast cancer and to compare ST266 treated burns with those treated with saline placebo controls.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: October 2015
• Est. primary completion date: July 2015
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• A signed IRB - approved Informed Consent;

• Women 18 - 80 years of age;

• Biopsy-proven diagnosis of breast cancer with the tumor surgically removed.

• Whole breast radiation with or without ipsilateral axilla radiation therapy recommended by her radiation oncologist.

• If a woman is of child-bearing potential, she and her partner must use an effective form of birth control.

• Willing to participate in the clinical study and comply with the requirements of the trial.

Exclusion Criteria:

• Abnormal liver or kidney function studies being greater than 2x the upper limit of normal.

• Patients on hemodialysis

• Psychiatric condition or substance abuse which in the Investigator's opinion may pose a threat to patient compliance;

• History of non-compliance with treatment or clinical visit attendance.

• Participation in an investigational trial within 30 days of study entry.

• Women who are pregnant or lactating

Related Conditions & MeSH terms

• Dermatitis
• Radiation-induced Dermatitis
• Radiodermatitis

Intervention

Biological:
• ST266
Patients will receive ST266 spray, to half the breast and saline to the other half (blinded) after each of ten consecutive radiation therapy treatments. ST266 and saline will be sprayed onto the breast to deliver 0.01 ml/cm2.

Locations

Country	Name	City	State
United States	Allegheny General Hospital	Pittsburgh	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Noveome Biotherapeutics, formerly Stemnion

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Cosmesis	Cosmesis will be evaluated by photography and investigator assessment using the cosmesis form in National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-39, A Randomized Phase III Study of Conventional Whole Breast Irradiation Versus Partial Breast Irradiation for Women with Stage 0, I, or II Breast Cancer. The following factors will be evaluated in the skin: telangiectasia, atrophy, scarring, pigmentation, erythema, fat necrosis, and fibrosis.	6 and 12 months post-treatment
Primary	Adverse Events (AEs) and Significant Adverse Events (SAEs)		Start of therapy through six week follow-up visit
Secondary	Skin inflammation		start of therapy through six week follow-up visit
Secondary	Quality of Life (QOL)scaled responses	Quality of Life (QOL) will be evaluated using a QOL Assessment (general to breast cancer patients receiving radiation therapy following tumor removal) and a QOL Supplement (specific to subjects receiving trial treatment). Both documents include subsets of questions, each with a different subscale. The assessments include both lifestyle QOL factors (sleep, activity, friends/family, general life enjoyment, etc.) and breast condition (pain, appearance, ect.). This secondary endpoint will focus on the QOL Supplement, comparing breast condition by treatment, noting changes in both the medial and lateral aspects breast including breast texture (thickening and hardness), pain, tenderness, shape, sensitivity, swelling, redness, itching, flaking skin, blistering and fluid leak. The patient will note, for each item, in which side of the breast they are experiencing the negative breast condition or if there is no difference.	start of therapy through one year follow-up